PBYI Key Statistics, Chart & Performance
The current stock price of PBYI is 5.95 USD. In the past month the price increased by 22.18%. In the past year, price increased by 101.7%.
PBYI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About PBYI
Company Profile
Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 172 full-time employees. The company went IPO on 2012-03-21. The firm is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The firm has in-licensed and is responsible for the global development and commercialization of alisertib. The company intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
Company Info
PUMA BIOTECHNOLOGY INC
10880 Wilshire Blvd., Suite 2150
Los Angeles CALIFORNIA 90024 US
CEO: Alan H. Auerbach
Employees: 172
Phone: 14242486500
PUMA BIOTECHNOLOGY INC / PBYI FAQ
Can you describe the business of PUMA BIOTECHNOLOGY INC?
Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 172 full-time employees. The company went IPO on 2012-03-21. The firm is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The firm has in-licensed and is responsible for the global development and commercialization of alisertib. The company intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
What is the stock price of PUMA BIOTECHNOLOGY INC today?
The current stock price of PBYI is 5.95 USD. The price decreased by -1% in the last trading session.
Does PBYI stock pay dividends?
PBYI does not pay a dividend.
How is the ChartMill rating for PUMA BIOTECHNOLOGY INC?
PBYI has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the expected growth for PBYI stock?
The Revenue of PUMA BIOTECHNOLOGY INC (PBYI) is expected to decline by -0.97% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of PBYI stock?
PUMA BIOTECHNOLOGY INC (PBYI) has a market capitalization of 299.82M USD. This makes PBYI a Micro Cap stock.
What is the outstanding short interest for PUMA BIOTECHNOLOGY INC?
The outstanding short interest for PUMA BIOTECHNOLOGY INC (PBYI) is 8.03% of its float.
PBYI Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PBYI. When comparing the yearly performance of all stocks, PBYI is one of the better performing stocks in the market, outperforming 95.06% of all stocks.
PBYI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PBYI. PBYI has an excellent profitability rating, but there are some minor concerns on its financial health.
PBYI Financial Highlights
Over the last trailing twelve months PBYI reported a non-GAAP Earnings per Share(EPS) of 0.74. The EPS increased by 54.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.44% | ||
| ROA | 18.23% | ||
| ROE | 32.08% | ||
| Debt/Equity | 0 |
PBYI Forecast & Estimates
7 analysts have analysed PBYI and the average price target is 4.76 USD. This implies a price decrease of -20% is expected in the next year compared to the current price of 5.95.
For the next year, analysts expect an EPS growth of -8.37% and a revenue growth -0.97% for PBYI